To better identify the subpopulation that could benefit most from the expression of CD11a, ICOS and CD137 (Fig. 4A), we compared the T-cell subsets expressing or lacking the markers in the three matched sites of NSCLC patients. This evidence concerns the gene TNFRSF9 and non-small cell lung carcinoma.